What is Ibrutinib?
Category: Prescription Drugs
Most popular types: Imbruvica
Ibrutinib is an experimental drug being tested for the purposes of treating cancers related to B-cells, which are a part of the immune system. This drug acts by inhibiting Bruton’s tyrosine kinase, a key component of the B-cell signalling pathway.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Chronic lymphocytic leukemia | 12 | 20 | |
| B cell prolymphocytic leukemia | 2 | 6 | |
| Diffuse large B-cell lymphoma | 1 | 0 | |
| Mantle cell lymphoma | 1 | 1 | |
| Multiple myeloma | 1 | 1 | |
| Non-Hodgkin's lymphoma | 1 | 0 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 2 | |
| Moderate | 8 | |
| Mild | 17 | |
| None | 2 |
Commonly reported side effects and conditions associated with Ibrutinib
| Side effect | Patients | Percentage |
|---|---|---|
| Diarrhea | 3 | |
| Dry skin | 2 | |
| Fatigue | 2 | |
| Thrombocytopenia (low platelet count) | 2 | |
| Agoraphobia | 1 | |
| Autoimmune hemolytic anemia | 1 |
Why patients stopped taking Ibrutinib
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Side effects too severe | 2 | |
| Did not seem to work | 1 |
Duration
Stopped taking Ibrutinib
| Duration | Patients | Percentage |
|---|---|---|
| Less than 1 month | 1 | |
| 1 - 6 months | 1 | |
| 1 - 2 years | 1 |
What people switch to and from
Patients started taking Ibrutinib after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Bendamustine (Treanda) | 3 | |
| Rituximab (Rituxan) | 3 | |
| Bortezomib (Velcade) | 1 | |
| Bortezomib-dexamethasone (Vd) | 1 | |
| Methotrexate (Apo-Methotrexate) | 1 |
Patients stopped taking Ibrutinib and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Bendamustine (Treanda) | 1 | |
| Rituximab (Rituxan) | 1 | |
| Venetoclax (Venclexta) | 1 |
Last updated: